Is Sermorelin Legal in Tennessee? How to Access It With a Prescription
HealthRX.com
Sermorelin needs a prescription from a licensed prescriber
Key numbers
- 8.0 cm/yrHeight velocity at 6 months in the 1-year pediatric study, up from 4.1 cm/yr at baselineSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- 30 microgramsStudy dose per kg given subcutaneously at bedtime in the pediatric program; not a recommended doseSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
- category 1FDA nomination list status for sermorelin acetate as a bulk substance for outsourcing facilitiesSource: fda.gov, as cited Nov 7, 2026
See the public record for Sermorelin
At a glance
- FDA-approved sermorelin / None since June 18, 2009 [1]
- Form available / Compounded only; not FDA-approved [2]
- Traditional compounding / Patient-specific prescription required [3]
- Outsourcing facilities / May supply providers for office stock [3]
- FDA safety-risk list / Sermorelin not on it [4]
- Outsourcing nomination list / Category 1, under evaluation [5]
- Sport / Prohibited at all times by WADA [6]
The Short Answer
Sermorelin can be dispensed in the US only as a compounded drug [2]. Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone that prompts the pituitary to release the body's own growth hormone; it is not growth hormone [7].
Federal law sets two pathways. A traditional compounding pharmacy works from a valid prescription for a specific patient. A registered outsourcing facility must follow current good manufacturing practice, is inspected by FDA on a risk-based schedule, must report adverse events, and may supply drugs either against a patient-specific prescription or against an order from a health care provider such as a hospital for office stock [3].
The Only Approved Sermorelin Is Gone
Sermorelin acetate was approved twice as Geref (EMD Serono): NDA 019863, a 0.05 mg/ampule product for evaluating the pituitary's ability to secrete growth hormone, approved December 28, 1990, and NDA 020443, 0.5 mg and 1 mg vials for idiopathic growth hormone deficiency in children with growth failure, approved September 26, 1997 [1].
The manufacturer notified FDA it was discontinuing the 0.05 mg product in July 2008 and the vials in December 2008, and asked FDA to withdraw the applications. FDA withdrew both approvals effective June 18, 2009 [1]. In March 2013 FDA determined Geref had not been withdrawn from sale for reasons of safety or effectiveness [1][9]. Those two uses were the only approved ones; Geref was never approved for adults, anti-aging, weight loss or athletic performance [1].
Where Sermorelin Sits on FDA's Lists
- It is not on FDA's list of bulk substances that may present significant safety risks [4].
- On FDA's list of nominated bulk substances for outsourcing facilities, sermorelin acetate is in category 1, under evaluation, flagged as a component of approved drugs [5].
- It does not appear in any category on FDA's list for state-licensed pharmacies and physicians [10].
- It is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [11].
Is There a Recommended Dose?
Geref's approvals were withdrawn in 2009, so no sermorelin product has a current FDA-approved dose [1]. Published doses are study doses, not recommendations: 30 micrograms per kg subcutaneously at bedtime in the pediatric program [12], and 0.5 mg or 1 mg subcutaneously twice daily for 14 days in 10 healthy older men [13]. In the 1-year pediatric study, height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months; fasting glucose did not change and sermorelin was well tolerated [12].
Sermorelin and Anti-Doping Rules
WADA's 2026 Prohibited List names sermorelin in S2.2.4 under growth hormone releasing factors, prohibited at all times, in and out of competition [6]. The 2027 List, in force January 1, 2027, names it as well [14].
Getting a Prescription
A sermorelin prescription needs a licensed prescriber and a pharmacy able to compound it: a traditional compounding pharmacy working from that patient's prescription, or a registered outsourcing facility [3]. HealthRX.com offers sermorelin by prescription.
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
FDA recalls of sermorelin products by Tennessee firms, 2013 to 2019
4 recall events in FDA records that name sermorelin and were started by firms in Tennessee, from 2013 to 2019. Each links to the record itself.
4 of 4 events shown
Main Street Family Pharmacy, LLC: recall of 4 sermorelin products
Class II recall, now terminated. Reason FDA lists: The firm received seven reports of adverse reactions in the form of skin abscesses potentially linked to compounded preservative-free methylprednisolone 80mg/ml 10 ml vials.
The Compounding Pharmacy of America: recall of 5 sermorelin products
Class II recall, now terminated. Reason FDA lists: Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterility.
Diabetes Corporation of America dba DCA Pharmacy: recall of one sermorelin product
Class II recall, now terminated. Reason FDA lists: Lack of Assurance of Sterility: A recent FDA inspection found that this product was not being compounded in an area appropriate for lyophilization which may lead to a lack of sterility assurance.
Anderson Compounding Pharmacy, Inc. DBA Anderson Compounding Pharmacy: recall of 2 sermorelin products
Class II recall, now terminated. Reason FDA lists: Lack of sterility assurance.
Frequently asked questions
Is sermorelin legal in Tennessee?
Is sermorelin FDA-approved?
Can a compounding pharmacy dispense sermorelin?
Is sermorelin banned in sport?
References
Show all 14 referencesHide references
- Federal Register :: Request Access.
- Official web page.
- Human Drug Compounding Laws | FDA.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- World Anti-Doping Agency.
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57.
- Registered Outsourcing Facilities | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996;81(3):1189-96.
- Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-5.
- World Anti-Doping Agency.